

Subject Index, 1982

Vol. 32, Nos. 1-6

A

Adair, Frank E.

Tribute to, 238-241

Ames test, 354-356

Ankylosing spondylitis

With pulmonary fibrosis and lung cancer (case report), 177-179

Assessment

Is cured early cancer truly cancer?, 2-9

B

Basal cell carcinoma

Mohs technique for, 322-329

Biography

Kaposi, Moriz, 340-341

Biopsy, 46-57

For breast cancer (one-step versus two-step procedure), 46-57, 368 (letter)

For cervix cancer, 88-89

Bladder cancer

Death rates for, 21
Incidence of, 22, 29
Mortality of, 17, 23
Survival rates for, 28, 31

Bleomycin

Toxicity of, 72

Bone cancer

Incidence of, 22, 30
Mortality of, 17, 23, 34-35
Survival rates for, 40

Brain and central nervous system cancer

Death rates for, 36-37
Incidence of, 22, 29-30, 38-39
Mortality of, 17, 23, 34-35
Survival rates for, 31, 40
In young adults, 42

Breast cancer, 173-176, 232-237, 242-256, 301-313

(See also, Breast Cancer Detection Demonstration Project, and Mammography)

American Cancer Society guidelines for detection of, 229

Biopsy for (one-step versus two-step procedure), 46-57, 368 (letter)

In black women (letter), 62-63

And breast-feeding (letter), 62-63, 320
California law on, 174

Comparison of trials of varying treatments for, 246, 248-255

Death rates for, 15, 20, 25, 27, 37
Early, 5-6

And emotionalism (letter), 372

Government-mandated patient education on, 174, 176, 371-372

Incidence of, 15, 22, 24, 29, 39

Lobular carcinoma in situ (classic), 232-237

Management of (request for participation in randomized trial), 231, 373-375 (letter)

Mortality of, 17, 23, 25, 35

And nipple banking (letter), 187-188

And risk factor study on, 301-313

Second cancers after, 288, 290

Surgery for primary operable, 242-256
Surgical versus radiotherapeutic management of, 231

Survival rates for, 28, 31, 40, 242, 244-246, 248, 249, 253-255

Therapeutic options for local control in, 173-176
In young adults, 33

Breast Cancer Detection Demonstration Project (BCDDP) 194-225

Biopsy rates in, 204, 206-207, 210-211, 215

Cancer detection rates in, 204, 206-207

Age-specific, 205, 208

Race-specific, 206, 209

Cancers detected in

By lesion size and modality, 217

By lesion size and nodal status, 218

By modality, lesion size, and nodal status, 220-223

Compared with Health Insurance Plan (HIP) of Greater New York

Subject Index, 1982

Vol. 32, Nos. 1-6

A

Adair, Frank E.

Tribute to, 238-241

Ames test, 354-356

Ankylosing spondylitis

With pulmonary fibrosis and lung cancer (case report), 177-179

Assessment

Is cured early cancer truly cancer?, 2-9

B

Basal cell carcinoma

Mohs technique for, 322-329

Biography

Kaposi, Moriz, 340-341

Biopsy, 46-57

For breast cancer (one-step versus two-step procedure), 46-57, 368 (letter)

For cervix cancer, 88-89

Bladder cancer

Death rates for, 21
Incidence of, 22, 29
Mortality of, 17, 23
Survival rates for, 28, 31

Bleomycin

Toxicity of, 72

Bone cancer

Incidence of, 22, 30
Mortality of, 17, 23, 34-35
Survival rates for, 40

Brain and central nervous system cancer

Death rates for, 36-37
Incidence of, 22, 29-30, 38-39
Mortality of, 17, 23, 34-35
Survival rates for, 31, 40
In young adults, 42

Breast cancer, 173-176, 232-237, 242-256, 301-313

(See also, Breast Cancer Detection Demonstration Project, and Mammography)

American Cancer Society guidelines for detection of, 229

Biopsy for (one-step versus two-step procedure), 46-57, 368 (letter)

In black women (letter), 62-63

And breast-feeding (letter), 62-63, 320
California law on, 174

Comparison of trials of varying treatments for, 246, 248-255

Death rates for, 15, 20, 25, 27, 37
Early, 5-6

And emotionalism (letter), 372

Government-mandated patient education on, 174, 176, 371-372

Incidence of, 15, 22, 24, 29, 39

Lobular carcinoma in situ (classic), 232-237

Management of (request for participation in randomized trial), 231, 373-375 (letter)

Mortality of, 17, 23, 25, 35

And nipple banking (letter), 187-188

And risk factor study on, 301-313

Second cancers after, 288, 290

Surgery for primary operable, 242-256

Surgical versus radiotherapeutic management of, 231

Survival rates for, 28, 31, 40, 242, 244-246, 248, 249, 253-255

Therapeutic options for local control in, 173-176

In young adults, 33

Breast Cancer Detection Demonstration Project (BCDDP) 194-225

Biopsy rates in, 204, 206-207, 210-211, 215

Cancer detection rates in, 204, 206-207

Age-specific, 205, 208

Race-specific, 206, 209

Cancers detected in

By lesion size and modality, 217

By lesion size and nodal status, 218

By modality, lesion size, and nodal status, 220-223

Compared with Health Insurance Plan (HIP) of Greater New York

- Screening Program, 214, 216, 224-225, 228-229
- Interval cancer rates in, 204, 206-207
 - Age specific, 211, 213
- Interval cancers detected in
 - By lesion size and nodal status, 219
- And mammography, 211, 214, 216-217, 220-221, 224-225, 228-229
- Minimal cancer detection rates in, 204, 206-207
 - Age-specific, 211-212
- Screening modalities in, 211, 214, 216-217, 220-224
- Surgical recommendation rates in, 204-205
- Women participating in
 - Age of, 195-198
 - Education of, 198, 200, 202
 - Income of, 198, 200, 202
 - Marital status of, 198, 200, 202
 - Medical history of, 201-203
 - Race of, 196, 198-199, 202
 - Recruitment of, 195-196

- Burkitt's lymphoma**, 144-161
- Clinical features of, 148-149
 - Cytologic features of, 144-147, 149
 - Etiology of, 145-148
 - Histologic features of, 144-145, 147, 149
 - And immunology, 144-145, 155-156, 370 (letter)
 - Staging of, 149-151
 - Treatment of, 149-155

C

- Carcinogens**, 261-279, 286-292, 348-362
- Androgenic anabolic steroids, 272
 - Antineoplastic drugs, 269, 286-292
 - Chemical-viral interactions, 357, 359
 - Correlation between teratogens and, 262-267
 - DES, 266-267
 - Estrogens, 270-271, 273
 - Hormones and nutritional factors, 358, 359
 - For humans, 350, 352
 - Immunosuppressive agents, 269-270
 - Methods for detecting, 267-269, 349-356
 - Clinical and epidemiologic studies, 349-350
 - Direct assays of DNA adducts, 356
 - And risk extrapolation to humans, 355, 359-360
 - Rodent bioassays, 350-354
 - Short-term tests, 354-357
 - Methoxypsoralen, 272, 274
 - Oral contraceptives, 271-272

- Phenacetin-containing analgesics, 274
- Phenytoin, 263, 274
- Species' various responses to, 350
- Tumor promoters, 357, 358

- Carcinoid tumors**, 92-99
- Of the appendix, 96, 98
 - Clinical presentation of, 92-95
 - Histology of, 94-95
 - History of, 92
 - Location of, 92-93
 - Malignant carcinoid syndrome, 95-96
 - Metastatic, 93-94, 98
 - And serotonin, 95-97
 - Survival rates for, 98
 - Treatment of, 96-98

- Carcinoma in situ**, 4-6
- Cervical intraepithelial neoplasia, 89-90
 - Lobular (classic), 232-237

Case reports

- Ankylosing spondylitis with fibrosis and carcinoma of the lung, 177-179
- Retroperitoneal seminoma, 78-81
- Stage C pure choriocarcinoma of the testis: a potentially curable lesion, 82-84
- Virilizing hepatoblastoma: precocious sexual development and partial response of pulmonary metastases to cis-platinum, 293-300

Cervix cancer

- Biopsy for, 88-89
- And cervical intraepithelial neoplasia, 89-90
- Early, 5

Chemotherapy

- And coagulability, 166
- For hepatoblastoma, 293-294, 296-298
- And hyperthermia, 126-127
- And second cancers, 286-292
- For testicular cancer, 66-77, 82-84

Cis-platinum

- For hepatoblastoma with pulmonary metastases (case report), 293, 296-298
- Toxicity of, 72

Classics in Oncology

- Idiopathic multiple pigmented sarcoma of the skin, 342-347
- Lobular carcinoma in situ: a rare form of mammary cancer, 232-237

Clinical trials

- For breast cancer, 46, 56, 231, 242-256

For fecal occult blood testing, 105-106
For melanoma, 314-317
Protocol for, 259-260
And surgical oncology, 44-45
Treatment in, 13

Coagulability in cancer patients, 162-172

And anticoagulants, 168-170
And chemotherapy, 166
Clotting factor deficiencies and platelet disorders, 168
Hemostatic sequence, 162-163, 165, 167
Hypercoagulable and hypocoagulable states, 163-164, 166
And metastatic growth, 163
Perioperative diagnosis of, 166-167

Colon and rectum cancer, 100-111

(See also, Colonoscopy)
Death rates for, 15, 20, 21, 25, 26
Fecal occult blood test in screening for, 100-112
High-risk patients for, 100-101, 185
Incidence of, 15, 22, 24, 29, 100
Mortality of, 17, 23, 25, 35, 100
Prevention of, 100, 103
Public attitudes toward (letter), 190-191
Survival rates for, 28, 31, 40

Colonoscopy, 180-186

And colonoscopic polypectomy, 181, 184
Indications for, in colorectal cancer, 180-181, 184-185

Colposcopy, 85-91

Definition of, 85-86
History of, 85-86
Versus conization, 85, 89-90
And workup of patient with abnormal Pap smear, 86-90

Conization

Versus colposcopy, 85, 89-90

Connective tissue cancer

Incidence of, 22
Mortality of, 17, 23
Survival rates for, 40

Cytomegalovirus (CMV)

And Kaposi's sarcoma, 335-337

Drugs, 258-279

(See also, specific drugs)
Determining carcinogenicity of, 267-269, 348-362
FDA regulation of, 259-260
Monitoring safety and efficacy of, 258-260
And mutagenesis, 261
And teratogenesis, 261-267

E

Early cancer, 2-9

Of the breast, 5-6
And carcinoma in situ, 2, 4-8
Of the cervix, 5
Diagnosis of, 2-8
Management of, 3, 5-8
And neoplastic transformation of cells, 3-4

Editorials

Progress in clinical cancer control, 363-365
Today's challenge for surgical oncology, 43-45

Endocervical curettage, 86-88

Endometrial cancer

And sampling for (letter), 189-190
And estrogen use, 270, 273
Pain during sampling for (letter), 188-189

Epstein-Barr virus (EBV)

And Burkitt's lymphoma, 145-149, 152, 156

Esophageal cancer

Death rates for, 21
Incidence of, 22, 29
Mortality of, 23
Survival rates for, 31

Estrogens

Carcinogenicity of, 270-274
Teratogenicity of, 264-266

Eye cancer, 322-329

(See also, Retinoblastoma)
Incidence of, 22, 30, 130
And the Mohs technique, 322-329
Mortality of, 23, 130-131, 139
Survival rates for, 130-131, 137

F

Fecal occult blood test, 100-111

Background of, 103

D

DES (diethylstilbestrol), 264, 266-267

And clinical trials, 101, 104-106, 108
Commercial tests available, 107, 109
And dietary recommendations (letter),
370-371
Guidelines for use of, 109-111
And nature of chemical reaction, 102,
104
Recommended methodology for, 107
And screening for colorectal cancer,
104-106, 108
Sensitivity of, 102, 108-109
Specificity of, 108
Stability of, 102, 108

Fibrosis, pulmonary

With ankylosing spondylitis and lung
cancer (case report), 177-179

G

Gestational trophoblastic neoplasia

Diagnostic tests for (letter), 191
Incidence of, in the Orient (letter),
191-192

H

Hepatoblastoma (case report), 293-300

And alphafetoprotein levels, 293-296,
298
Chemotherapy for, 293-294, 296-298
And endocrinologic investigations,
293-296, 298
And precocious sexual development,
293-294, 296, 298

Hodgkin's disease

Death rates for, 36-37
Incidence of, 22, 38-39
And mononucleosis (letter), 368
Mortality of, 17, 23, 34-35
Second cancers after, 287, 289
Survival rates for, 28, 31, 40
In young adults, 42

Hospice concept, 141-143

Hyperthermia, whole body, 123-128

Cancer response to, 126-127
And chemotherapy, 126-127
History of, 123-124
Methodology of, 124-126
And radiation therapy, 127

I

Immunology

And Burkitt's lymphoma, 144-145,
155-156, 370 (letter)

And current outbreak of Kaposi's
sarcoma and opportunistic infections,
331, 334-337

K

Kaposi, Moriz

Biography of, 340-341

Kaposi's sarcoma, 330-340, 342-347

Current outbreak of opportunistic
infections and, 330-339
First description of (classic), 340,
342-347

Kidney cancer

(See also, Renal cell carcinoma)
Incidence of, 22, 29-30
Mortality of, 17, 23
Survival rates for, 28, 31

L

Laryngectomees

Care of, 366-367

Larynx cancer

(See also, Laryngectomees)
Incidence of, 22, 29
Mortality of, 23
Survival rates for, 28, 31

Leukemia

After breast cancer, 288, 290
Death rates for, 20, 21, 25, 27, 36-37
After Hodgkin's disease, 287-289
Incidence of, 15, 22, 24, 30, 38
Mortality of, 17, 23, 25, 34-35
After ovarian carcinoma, 287-289
Survival rates for, 28, 31, 40
In young adults, 32-33

Liver cancer

(See also, Hepatoblastoma)
Death rates for, 20, 21
Incidence of, 22, 29-30
Mortality of, 23

Lobular carcinoma in situ (classic), 232-237

Lung cancer

And ankylosing spondylitis with
pulmonary fibrosis (case report),
177-179
Death rates for, 15, 20, 21, 25-26
Incidence of, 15, 22, 24, 29
Mortality of, 17, 23, 25, 34
Survival rates for, 28, 31, 40

Lymph node dissection

For melanoma, 314-317

Lymphomas

(See also, Burkitt's lymphoma, and Hodgkin's disease)

Death rates for, 36

Incidence of, 22, 30, 38, 39

Mortality of, 23, 34, 35

Survival rates for, 31, 40

In young adults, 42

M

Malignant melanoma, 113-122, 314-317

Lymph node dissection for, 314-317

Prognostic guidelines for, 113-122

Mammography, 226-230

American Cancer Society statement on, 226-230

In the Breast Cancer Detection Demonstration Project, 211, 214, 216-217, 220-221, 224-225, 228-229

And the radiation issue, 226-228

Mohs technique, 322-329

Multiple myeloma

Incidence of, 22

Mortality of, 23

Survival rates for, 28

N

Neurofibrosarcoma

And irradiation (letter), 319

O

Opinions

California breast cancer law and government-mandated patient education, 173-176

Can colposcopy replace conization?, 85-91

Case for the one-step biopsy procedure for breast cancer, 46-50

Case for the two-step biopsy procedure for breast cancer, 51-57

Concept of hospice, 141-143

Lymph node dissection for stage I melanoma: the unresolved dilemma, 314-317

Risk of a second malignancy related to the use of cytotoxic chemotherapy, 286-292

Oral cancer

Death rates for, 15, 25, 26

Incidence of, 15, 22, 24, 29

Mortality of, 23, 25

Survival rates for, 31

Oral contraceptives

Carcinogenicity of, 271-272

Teratogenicity of, 265

Ovarian cancer

Death rates for, 15, 20

Incidence of, 15, 22, 29, 39

Mortality of, 17, 23, 35

Second cancers after, 287-289

Survival rates for, 28, 31, 40

P

Pancreatic cancer

And coffee (letter), 368-369

Death rates for, 15, 20, 21, 25

Incidence of, 15, 22, 24, 29

Mortality of, 17, 23, 25

And percutaneous transhepatic bypass (letter), 318-319

Pap smear

Workup of patient with abnormal, 86-90

Pneumocystis carinii

Current outbreak of Kaposi's sarcoma and, 330-339

Postmastectomy lymphedema (letter), 63

Prostate cancer

Death rates for, 15, 21, 25, 27

Incidence of, 15, 22, 24, 29

Mortality of, 17, 23, 25

Survival rates for, 28, 31

Psychosocial aspects of cancer, 10-14

Attitudes toward colon and rectum cancer (letter), 190-191

Attitudes toward unproven cancer remedies, 10-14

Hospice concept, 141-143

R

Renal cell carcinoma, 280-285

Clinical evaluation of, 281

Clinical manifestations and diagnosis of, 280-281

Etiology of, 280
Prognosis of, 280
Staging of, 281-283
Treatment of, 282, 284

Retinoblastoma, 130-140

Diagnosis of, 132-133
And ancillary tests, 135-136
Differential, 134-135
Genetics of, 131
Incidence of, 30, 130, 369-370
And leukokoria, 131-133
Mortality of, 130-131, 139
Reese-Ellsworth classification system
for, 132
And second nonocular tumors, 139
Signs and symptoms of, 131-132
Survival rates for, 130-131, 137
Treatment of, 137-139
And vitreous seeding, 133

S

Screening

For breast cancer, 194-230
For colon and rectum cancer, 100-111
For endometrial cancer (letter),
189-190

Second cancers, 286-292

After antineoplastic drugs, 262-263,
269, 286-292
After breast cancer, 288, 290
After Hodgkin's disease, 287, 289
After ovarian carcinoma, 287-289
After retinoblastoma, 139

Seminoma, 66, 78-81

Chemotherapy for, 74, 76
Retroperitoneal (case report), 78-81

Serotonin

And carcinoid tumors, 95-97
Degradation of, 96-97
Synthesis of, 95-97

Simonton, O. Carl, 58-61

American Cancer Society's evaluation
of, 58-60
And Cancer Counseling and Research
Center, 58-59

Skin cancer

(See also, Malignant melanoma)
Death rates for, 15, 27
Incidence of, 15, 22
Mortality of, 17, 23, 34
Survival rates for, 31, 40, 114,
116-121

In young adults, 42

Small intestine cancer

Incidence of, 22
Mortality of, 23

Soft tissue cancer

Incidence of, 30

Staging

Of Burkitt's lymphoma, 149-151
Of renal cell carcinoma, 281-283
Of retinoblastoma, 132
Of testicular cancer, 66-67

Statistics, cancer, 15-31

(See also, specific sites)

Death rates

Around the world, 26-27
By geographic location, 25
By site and sex, 15, 20-21
For young adults, 33, 36-37

Incidence

In children, 30
By geographic location, 24
By site and sex, 15, 22
By stage at diagnosis, 29
In young adults, 38-39

Mortality

By geographic location, 25
By site and sex, 23
Leading causes of, 16
By age and sex, 18-19
In children, 30
Leading sites of, 17
In young adults, 34-35

Survival rates

By site and race, 28
Trends in survival by race, 31
For young adults, 40

Stomach cancer

Death rates for, 20, 21, 25, 27
Incidence of, 24, 29
Mortality of, 17, 23, 25
Survival rates for, 28, 31

Surgery, 242-256

For carcinoid tumors, 96, 98
Mohs technique, 322-329
For primary operable breast cancer,
242-256
For testicular cancer, 71

Surgical oncology (editorial), 43-45

Sympathetic nervous system cancer

Incidence of, 30

T

Teratogens, 261-267

- Androgenic anabolic steroids, 265
- Antineoplastic drugs, 262-263
- Correlation between carcinogens and, 262-267
- DES, 264, 266-267
- Estrogens, 264, 266-267
- Oral contraceptives, 265
- Phenytoin, 263

Testicular cancer, 66-77, 82-84

- (See also, Seminoma)
- Chemotherapy for, 66-77, 82-84
 - Adjuvant, 74
 - History of, 66-67
 - Long-term complications of, 72-73
 - Maintenance, 71-72, 83-84
 - And PVB (cis-platinum, vinblastine, and bleomycin) programs, 68, 70-71, 74-75
 - Salvage, 73
 - Toxicity of, 72
 - And VAB (vinblastine, actinomycin D, and bleomycin) programs, 68-69, 82
- Choriocarcinoma (case report), 82-84
- Death rates for, 36
- And extragonadal germ cell tumors, 76
- Incidence of, 22, 38
- And indications for therapy, 66
- Mortality of, 17, 23, 34
- Prognostic factors for, 71, 75
- Staging of, 66-67
- Surgery for, 71
- Survival rates for, 40, 71, 76
- In young adults, 42, 66

Thyroid cancer

- Incidence of, 22, 29, 38-39
- Mortality of, 23
- Survival rates for, 31, 40
- In young adults, 42

Toxicity

- Of bleomycin, 72
- Of cis-platinum, 72
- Of thalidomide, 258
- Of vinblastine, 72

Tribute

- Adair, Frank E., 238-241

U

Unproven methods of cancer management, 10-14, 58-61

- American Cancer Society Committee on, 11
- Common qualities of, 12
- And O. Carl Simonton, 58-61
- Physician's response to, 12-13
- Psychological hazards of, 12
- Psychological reasons for seeking, 10-14
- Types of, 12

Uterine cancer

- Death rates for, 15, 20, 25, 27, 37
- Incidence of, 15, 22, 24, 29, 39
- Mortality of, 17, 23, 25, 35
- Survival rates for, 28, 31, 40
- In young adults, 42

V

Vinblastine

- Toxicity of, 72

W

Wells, H. G. on cancer (letter), 63-64

Wilms' tumor

- And neurofibromatosis (letter), 320

Y

Young adults and cancer, 32-42

- Of the brain and central nervous system, 42
- Of the breast, 33
- Death rates and mortality, 32-37
- Hodgkin's disease, 42
- Incidence of, 38-39
- Leukemia, 32-33
- Non-Hodgkin's lymphomas, 42
- Of the skin, 42
- Survival rates for, 40
- Of the testis, 42
- Of the thyroid gland, 42
- Treatment by various modalities, 41
- Of the uterus, 42

Author Index, 1982

Vol. 32, Nos. 1-6

A

Abbassi, V., 293-300
Abramson, D. H., 130-140
Arshad, R. R., 293-300

B

Baker, L. H., 194-225
Baldwin, M., 100-112
Beaton, H. L., 92-99
Braun, M., 340-341
Bretsky, S. S., 242-256
Brigden, M. L., 82-84
Bull, J. M. C., 123-128

C

Callahan, A., 322-329
Callahan, M. A., 322-329
Caprini, J. A., 162-172
Carter, S. K., 173-176
Cascinelli, N., 316-317
Cody, H. S., III, 242-256
Comisarow, R. H., 82-84
Curran, J. W., 330-339

D

Day, C. L., Jr., 113-122
Drasga, R. E., 66-77

E

Einhorn, L. H., 66-77

F

Fitzpatrick, T. B., 113-112

Fleisher, M., 100-112
Foote, F. W., Jr., 234-237

H

Haverkos, H. W., 330-339
Hickman, B. T., 78-81
Holland, J. C., 10-14
Holleb, A. I., 43-45, 238-241, 363-365
Hoy, G. R., 293-300
Hutter, R. V. P., 2-9, 232-233

J

Jones, G. W., 280-285

K

Kaposi, M., 342-347
Kinne, D. W., 46-50
Kopf, A. W., 113-122

L

Leone, L. A., 141-143
Lew, R. A., 113-122

M

Margolese, R. G., 51-57
Mihm, M. C., Jr., 113-122
Monheit, G. D., 322-329
Mushinski, M. H., 301-313

O

Overholt, B. F., 180-186

P

Petrelli, N. J., 314-315

R

Reimer, R. R., 286-292
Richart, R. M., 85-91
Routh, A., 78-81

S

Schottenfeld, D., 258-279
Seidman, H., 301-313
Sener, S. F., 162-172
Shankar, P. S., 177-179
Sherlock, P., 100-112

Silverberg, E., 15-42
Sinks, L. F., 293-300
Smith, E. E., 78-81
Sober, A. J., 113-122
Stellman, S. D., 301-313
Stewart, F. W., 234-237
Sullivan, L. D., 82-84

T

Townsend, D. E., 85-91

U

Urban, J. A., 242-256

V

Veronesi, U., 316-317

W

Weinstein, I. B., 348-362
Williams, S. D., 66-77
Winawer, S. J., 100-112
Woo, S. Y., 293-300

Z

Ziegler, J. L., 144-161

